4.7 Article

Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation

Journal

BLOOD
Volume 125, Issue 18, Pages 2855-2864

Publisher

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2014-11-608406

Keywords

-

Categories

Funding

  1. Fondazione Cariplo [Ricerca Biomedica 2012/0683]
  2. European Union [322093]
  3. Associazione Italiana per la Ricerca sul Cancro [MFAG 10607, IG 14687]
  4. Italian Ministry of Health [GR-2008-1135082, GR-2011-02347324]
  5. National Institutes of Allergy and Infectious Diseases
  6. Humanitas Intramural Research and Clinical Funding Programs
  7. Fondazione Italiana per la Ricerca sul Cancro
  8. Wellcome Trust [100326/Z/12/Z] Funding Source: researchfish

Ask authors/readers for more resources

Early T-cell reconstitution following allogeneic transplantation depends on the persistence and function of T cells that are adoptively transferred with the graft. Posttransplant cyclophosphamide (pt-Cy) effectively prevents alloreactive responses from unmanipulated grafts, but its effect on subsequent immune reconstitution remains undetermined. Here, we show that T memory stem cells (TSCM), which demonstrated superior reconstitution capacity in preclinical models, are the most abundant circulating T-cell population in the early days following haploidentical transplantation combined with pt-Cy and precede the expansion of effector cells. Transferred naive, but not TSCM or conventional memory cells preferentially survive cyclophosphamide, thus suggesting that posttransplant TSCM originate from naive precursors. Moreover, donor naive T cells specific for exogenous and self/tumor antigens persist in the host and contribute to peripheral reconstitution by differentiating into effectors. Similarly, pathogen-specific memory T cells generate detectable recall responses, but only in the presence of the cognate antigen. We thus define the cellular basis of T-cell reconstitution following pt-Cy at the antigen-specific level and propose to explore naive-derived TSCM in the clinical setting to overcome immunodeficiency.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available